Production (Stage)
Verve Therapeutics, Inc.
VERV
$4.36
-$0.02-0.46%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
5/24/2025
-
MarketBeat
5/23/2025
-
MarketBeat
5/23/2025
-
Tickeron - Stocks
5/23/2025
-
MarketBeat
5/22/2025
-
MarketBeat
5/21/2025
-
Zacks Investment Research
5/21/2025
-
MarketBeat
5/21/2025
-
MarketBeat
5/20/2025
-
MarketBeat
5/20/2025
-
MarketBeat
5/20/2025
-
MarketBeat
5/19/2025
-
Simply Wall St
5/19/2025
-
Simply Wall St
5/19/2025
-
Ticker Report
5/18/2025
-
MarketBeat
5/16/2025
-
Ticker Report
Jacobs Levy Equity Management Inc. Acquires 288,678 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)
5/15/2025
-
MarketBeat
5/14/2025
-
TipRanks Financial Blog
5/14/2025
-
GuruFocus
5/14/2025
-
Zacks Investment Research
5/14/2025
-
GuruFocus
5/14/2025
-
GuruFocus
5/14/2025
-
The Fly
5/14/2025
-
Globe Newswire
5/13/2025
-
Zacks Investment Research
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 603 0070
Address
201 Brookline Avenue
Boston, MA 02215
Boston, MA 02215
Country
Year Founded
Business Description
Sector
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include...
more